Of the recruited patients, 78 (16.6 %) were not treated with DEX implant for the following reasons: treated with anti-VEGF (n = 24), treated with laser (n = 7), presented with ischemia (n = 13), had glaucoma (n = 7), BCVA too low (n = 4), BCVA too high (n = 3), and other (n = 20). This evidence concerns the gene VEGFA and ischemia.